Hepion Pharmaceuticals Announces Death of Director, Thomas Adams
January 12 2022 - 8:00AM
It is with profound sadness that Hepion Pharmaceuticals, Inc.
(NASDAQ:HEPA) announces the passing of Thomas Adams, Ph.D., a
member of its Board of Directors. Dr. Adams died of natural causes
on January 9, 2022.
A seasoned biotechnology veteran, Dr. Adams was
appointed to Hepion’s Board in September 2016.
"We are deeply saddened by the loss of our dear
friend and colleague,” said Hepion’s Chairman, Gary S. Jacob, Ph.D.
“On behalf of the Company’s Board of Directors, management team and
employees, I would like to extend our deepest sympathies to Tom’s
family. Tom was a larger-than-life executive and entrepreneur, who
brought his remarkable passion, experience and energy to Hepion. He
will be greatly missed.”
About Hepion
Pharmaceuticals
The Company's lead drug candidate, rencofilstat,
is a potent inhibitor of cyclophilins, which are involved in many
disease processes. Rencofilstat is currently in clinical-phase
development for the treatment of NASH, with the potential to play
an important role in the overall treatment of liver disease - from
triggering events through to end-stage disease. Rencofilstat has
been shown to reduce liver fibrosis and hepatocellular carcinoma
tumor burden in experimental models of NASH, and has demonstrated
antiviral activities towards HBV, HCV, and HDV through several
mechanisms, in nonclinical studies. In November 2021, the U.S. Food
and Drug Administration (“FDA”) granted Fast Track designation for
rencofilstat for the treatment of NASH. That was soon followed in
December 2021 by the FDA’s acceptance of Hepion’s investigational
new drug (IND) application for rencofilstat for the treatment of
hepatocellular carcinoma (HCC).
Hepion has created a proprietary AI platform,
called AI-POWR™, which stands for Artificial
Intelligence - Precision Medicine;
Omics (including genomics, proteomics,
metabolomics, transcriptomics, and lipidomics);
World database access; and
Response and clinical outcomes. Hepion intends to
use AI-POWR™ to help identify which NASH patients will best respond
to rencofilstat, potentially shortening development timelines and
increasing the delta between placebo and treatment groups. In
addition to using AI-POWR™ to drive its ongoing NASH clinical
development program, Hepion intends to use the platform to identify
additional potential indications for rencofilstat to expand the
company's footprint in the cyclophilin inhibition therapeutic
space.
For further information, please contact:
Stephen KilmerHepion Pharmaceuticals Investor
RelationsDirect: (646) 274-3580skilmer@hepionpharma.com
Hepion Pharmaceuticals (NASDAQ:HEPA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Hepion Pharmaceuticals (NASDAQ:HEPA)
Historical Stock Chart
From Sep 2023 to Sep 2024